ASBP

Aspire Biopharma Holdings, Inc.
CAPPED RATING

Aspire Biopharma Holdings, Inc. (ASBP) is rated C (2.2/5) on Deltasharpe Prism, scored against Consumer Cyclical sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (F). The rating has held at C for 8 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
F
Factor Score 0.0 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
B+
Factor Score 3.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin -25.0%
Price Return 3M 5.5%
Price Return 12M 91.9%
Catalyst Signal 0.00
Market Cap $11.3M
TTM Revenue $97.7K
Price / Sales 115.8
ROE N/M

Historical Factor Score Progression

Held C for 8 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 F (0.0) C+ (2.5) C (2.2) B+ (3.6) C+ (2.6) C (2.2)
2026-11-10 F (0.0) C+ (2.5) C (2.2) B+ (3.6) C+ (2.5) C (2.2)
2026-11-03 F (0.0) C+ (2.5) C (2.3) B+ (3.5) C+ (2.5) C (2.2)
2026-10-27 F (0.0) C+ (2.5) C (2.2) B+ (3.7) C+ (2.6) C (2.2)
2026-10-20 F (0.0) C+ (2.5) C (2.2) B+ (3.7) C+ (2.6) C (2.2)
Page 1 of 4